Generic Name and Formulations:
Fulvestrant 50mg/mL; soln for IM inj.
Indications for FASLODEX:
Hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Give by IM inj slowly (1–2 mins/injection). 500mg (as two 5mL injections, one in each buttock) on days 1, 15, 29, then once per month thereafter. Moderate hepatic impairment: 250mg (as one 5mL injection) on days 1, 15, 29, then once per month thereafter.
Estrogen receptor antagonist.
Bleeding diatheses, thrombocytopenia, or anticoagulant use. Moderate to severe hepatic impairment. Pregnancy (Cat.D; avoid); exclude pregnancy before starting. Nursing mothers: not recommended.
Inj site pain, GI upset, bone pain, arthralgia, headache, back pain, fatigue, pain in extremity, hot flash, anorexia, asthenia, musculoskeletal pain, cough, dyspnea, constipation; increased hepatic enzymes, hypersensitivity reactions.
Hepatic (CYP3A4); 99% protein bound.
Fecal (primarily), renal.
Prefilled syringe kit (2 x 5mL)—1
- Paleo Diet: Should It Stay in the Stone Age?
- Risks and Recommendations: The Use of NSAIDs in Patients With Cardiovascular Disease
- Neurological Complications Caused by "Skinny Jeans"
- Popular Restaurant Meals That Pack a Caloric Punch
- What's the Secret to Longevity? Lessons from "Blue Zones" Worldwide